| | 130929-57-6 Basic information More.. |
| Product Name: | Entacapone | | Synonyms: | (E)-2-Cyano-3-(3，4-dihydroxy-5-nitrophenyl)-N，N-diethyl-2-pmpenamide;Entacapone (150 mg);(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enaMide;2-PropenaMide,2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-;(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide;Entacapone (isomer E);(E)-2-cyano-3-(5-(dihydroxyamino)-3,4-dioxocyclohexa-1,5-dienyl)-N,N-diethylacrylamide;ENTACAPONE | | CAS: | 130929-57-6 | | MF: | C14H15N3O5 | | MW: | 305.29 | | EINECS: | 212-686-0 | | Mol File: | 130929-57-6.mol |  |
Use
Entacapone was introduced in Finland, Germany and Sweden as an
adjunctive treatment with L-dopa in Parkinson’s disease. Entacapone is the
second drug in its class to reach the market; it can be obtained by
basecatalyzed condensation of the corresponding benzaldehyde with a
cyanoacetamide. Entacapone is a highly selective and orally-active catechol-0-
methyltransferase (COMT) inhibitor ; by inhibiting metabolism of L-dopa when
given as an adjuvant in patients with Parkinson’s disease, Entacapone markedly
prolongs the effects of L-dopa and improves its bioavailability. Results from
clinical studies showed that 200mglday Entacapone coadministered with L-dopa
lowered the dose of the latter required to reduce fluctuations in motor
performance.
- Entacapone
-
- US $0.00-0.00 / kg
- 2025-05-23
- CAS:130929-57-6
- Min. Order: 1kg
- Purity: 98
- Supply Ability: 1000
- Entacapone
-
- US $30.00-73.00 / mg
- 2025-05-22
- CAS:130929-57-6
- Min. Order:
- Purity: 98.80%
- Supply Ability: 10g
- Entacapone
-
- US $0.00-0.00 / mg
- 2025-05-21
- CAS:130929-57-6
- Min. Order: 30mg
- Purity: 95
- Supply Ability: 100000
|
|
130929-57-6
Recommend Suppliers |
|